Want to see SE:VICO full AI Analyst Report?
VICO Stock Chart & Stats
kr10.74
kr0.06(0.53%)
At close: 4:00 PM EDT
kr10.74
kr0.06(0.53%)
Day’s Range― - ―
52-Week Rangekr8.56 - kr18.24
Previous CloseN/A
Volume244.45K
Average Volume (3M)1.02M
Market Cap
kr2.49B
Enterprise Valuekr2.64B
Total Cash (Recent Filing)kr905.64M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Nov 05, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.92
Shares Outstanding281,644,500
10 Day Avg. Volume1,420,707
30 Day Avg. Volume1,021,950
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)2.47
Price to Sales (P/S)710.16
P/FCF Ratio-7.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr38.00Price Target Upside253.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.81
Revenue Forecast (FY)kr3.67M
Bulls Say, Bears Say
Bulls Say
Low LeverageAn effectively debt-free balance sheet reduces solvency and interest burdens while preserving flexibility to fund clinical development. The sizable equity base provides a financial cushion, although continued losses could reduce it over time.
Focused Clinical PipelineConcentration on severe lung diseases and a defined lead program gives Vicore a clear strategic focus. Progress in buloxibutid could create meaningful long-term value if clinical development and regulatory approval succeed.
Recent Revenue GrowthThe reported increase in trailing revenue indicates some improvement in the company’s current revenue base, despite its small scale. If sustained or expanded through partnerships and future products, this could gradually reduce reliance on external funding.
Bears Say
Heavy Cash BurnDeeply negative operating and free cash flow means Vicore cannot currently fund its development program from internal cash generation. Persistent deterioration increases dependence on financings, partnerships, or other capital sources and raises dilution risk.
Severe Ongoing LossesVery large losses relative to revenue show that the business remains far from self-sustaining. Unless clinical assets generate materially higher revenue or expenses decline, earnings weakness can continue consuming equity and constrain investment capacity.
No Established Commercial Revenue BaseVicore’s future monetization depends on achieving regulatory and commercial success because recurring product revenue is not established. This creates a durable business risk: development setbacks or delays could prolong losses and external funding needs.
Vicore Pharma Holding AB News
VICO FAQ
What was Vicore Pharma Holding AB’s price range in the past 12 months?
Vicore Pharma Holding AB lowest stock price was kr8.56 and its highest was kr18.24 in the past 12 months.
What is Vicore Pharma Holding AB’s market cap?
Vicore Pharma Holding AB’s market cap is kr2.49B.
When is Vicore Pharma Holding AB’s upcoming earnings report date?
Vicore Pharma Holding AB’s upcoming earnings report date is Nov 05, 2026 which is in 13 days.
How were Vicore Pharma Holding AB’s earnings last quarter?
Vicore Pharma Holding AB released its earnings results on Aug 21, 2026. The company reported -kr0.51 earnings per share for the quarter, missing the consensus estimate of -kr0.41 by -kr0.1.
Is Vicore Pharma Holding AB overvalued?
According to Wall Street analysts Vicore Pharma Holding AB’s price is currently Undervalued.
Does Vicore Pharma Holding AB pay dividends?
Vicore Pharma Holding AB does not currently pay dividends.
What is Vicore Pharma Holding AB’s EPS estimate?
Vicore Pharma Holding AB’s EPS estimate is -0.51.
How many shares outstanding does Vicore Pharma Holding AB have?
Vicore Pharma Holding AB has 281,644,500 shares outstanding.
What happened to Vicore Pharma Holding AB’s price movement after its last earnings report?
Vicore Pharma Holding AB reported an EPS of -kr0.51 in its last earnings report, missing expectations of -kr0.41. Following the earnings report the stock price went down -0.362%.
Which hedge fund is a major shareholder of Vicore Pharma Holding AB?
Currently, no hedge funds are holding shares in SE:VICO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vicore Pharma Holding AB
Vicore Pharma Holding AB (publ), a Gothenburg, Sweden-based company, specializes in the discovery and advancement of therapies for rare lung conditions. Its core pipeline features VP01, an orally administered small molecule currently in Phase II clinical trials for indications such as interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19. The company is also progressing VP02, a novel formulation and delivery approach for an established immunomodulatory compound, which is in preclinical development for treating IPF. Vicore maintains strategic alliances, including a development cooperation with Emeriti Bio AB, a licensing arrangement with Nanologica AB (publ), and a collaboration with Alex Therapeutics AB focused on creating and clinically validating a digital therapeutic (DTx) built on the Alex DTx platform. Established in 2000, the company was formerly known as Mintage Scientific AB.
VICO Stock 12 Month Forecast
Average Price Target
kr38.00
▲(253.82% Upside)
Technical Analysis
Hansa Biopharma AB
―
Medivir AB
―
BioInvent International AB
―
SynAct Pharma AB
―
Cantargia AB
―